Non-vanillyl resiniferatoxin analogues as potent and metabolically stable transient receptor potential vanilloid 1 agonists

被引:8
|
作者
Choi, Hyun-Kyung [1 ]
Choi, Sun [2 ,3 ]
Lee, Yoonji [2 ,3 ]
Kang, Dong Wook [1 ]
Ryu, HyungChul [1 ]
Maeng, Han-Joo [1 ]
Chung, Suk-Jae [1 ]
Pavlyukovets, Vladimir A. [4 ]
Pearce, Larry V. [4 ]
Toth, Attila [4 ]
Tran, Richard [4 ]
Wang, Yun [4 ]
Morgan, Matthew A. [4 ]
Blumberg, Peter M. [4 ]
Lee, Jeewoo [1 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[2] Ewha Womans Univ, Coll Pharm, Div Life & Pharmaceut Sci, Seoul 120750, South Korea
[3] Ewha Womans Univ, Natl Core Res Ctr Cell Signaling & Drug Discovery, Seoul 120750, South Korea
[4] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Resiniferatoxin; TRPV1; agonist; ANALGESIC AGENTS; IODO-RESINIFERATOXIN; CAPSAICIN RECEPTOR; GANGLION NEURONS; VR1; ANTAGONIST; BINDING; TRPV1; RTX; DESENSITIZATION;
D O I
10.1016/j.bmc.2008.11.085
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of non-vanillyl resiniferatoxin analogues, having 4-methylsulfonylaminophenyl and fluorophenyl moieties as vanillyl surrogates, have been investigated as ligands for rat TRPV1 heterologously expressed in Chinese hamster ovary cells. Although lacking the metabolically problematic 4-hydroxy substituent on the A-region phenyl ring, the compounds retained substantial agonist potency. Indeed, the 3-methoxy-4-methylsulfonylaminophenyl analog (1) was modestly (2.5-fold) more potent than RTX, with an EC50 = 0.106 nM. Further, it resembled RTX in its kinetics and pattern of stimulation of the levels of intracellular calcium in individual cells, as revealed by imaging. Compound 1 displayed modestly enhanced in vitro stability in rat liver microsomes and in plasma, suggesting that it might be a pharmacokinetically more favorable surrogate of resiniferatoxin. Molecular modeling analyses with selected analogues provide evidence that the conformational differences could affect their binding affinities, especially for the ester versus amide at the B-region. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:690 / 698
页数:9
相关论文
共 50 条
  • [1] The effects of vanilloid analogues structurally related to capsaicin on the transient receptor potential vanilloid 1 channel
    Oka, Y.
    Takahashi, K.
    Ohta, T.
    BIOCHEMISTRY AND BIOPHYSICS REPORTS, 2022, 30
  • [2] Asymmetric synthesis and receptor activity of chiral simplified resiniferatoxin (sRTX) analogues as transient receptor potential vanilloid 1 (TRPV1) ligands
    Kim, Myeong Seop
    Ki, Yooran
    Ahn, Song Yeon
    Yoon, Suyoung
    Kim, Sung-Eun
    Park, Hyeung-Geun
    Sun, Wei
    Son, Karam
    Cui, Minghua
    Choi, Sun
    Pearce, Larry V.
    Esch, Timothy E.
    DeAndrea-Lazarus, Ian A.
    Blumberg, Peter M.
    Lee, Jeewoo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 382 - 385
  • [3] Discovery of potent transient receptor potential vanilloid 1 antagonists: Design and synthesis of phenoxyacetamide derivatives
    Takahashi, Eiki
    Hirano, Noriyuki
    Nagahara, Takashi
    Yoshikawa, Satoru
    Momen, Shinobu
    Yokokawa, Hiroshi
    Hayashi, Ryoji
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3154 - 3156
  • [4] Synthesis of Mavatrep: A Potent Antagonist of Transient Receptor Potential Vanilloid-1
    Wells, Kenneth M.
    Mehrman, Steven J.
    Abdel-Magid, Ahmed F.
    Ferraro, Caterina
    Scott, Lorraine
    Zhong, Hua Marlon
    Teleha, Christopher A.
    Ballentine, Scott
    Li, Xun
    Russell, Ronald K.
    Spink, Jan M.
    Diamond, Craig
    Youells, Scott
    Zhang, Yongzheng
    Tsay, Fuh-Rong
    Cesco-Cancia, Sergio
    Manzo, Stephen M.
    Beauchamp, Derek A.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2015, 19 (11) : 1774 - 1783
  • [5] Novel phenylpiperazine derivatives as potent transient receptor potential vanilloid 1 antagonists
    Jing, Lina
    Liu, Chunxia
    CHEMICAL BIOLOGY & DRUG DESIGN, 2024, 104 (01)
  • [6] Modulation of Transient Receptor Vanilloid 1 Activity by Transient Receptor Potential Ankyrin 1
    Spahn, Viola
    Stein, Christoph
    Zoellner, Christian
    MOLECULAR PHARMACOLOGY, 2014, 85 (02) : 335 - 344
  • [7] The desensitization of the transient receptor potential vanilloid 1 by nonpungent agonists and its resensitization by bradykinin
    Alsalem, Mohammad
    Aldossary, Sara A.
    Haddad, Mansour
    Altarifi, Ahmad
    Kalbouneh, Heba
    Azab, Belal
    Mustafa, Ayman G.
    Jaffal, Sahar M.
    El-Salem, Khalid
    NEUROREPORT, 2020, 31 (11) : 781 - 786
  • [8] Novel Radiolabeled Vanilloid with Enhanced Specificity for Human Transient Receptor Potential Vanilloid 1 (TRPV1)
    Pearce, Larry V.
    Ann, Jihyae
    Jung, Aeran
    Thorat, Shiyaii A.
    Herold, Brienna K. A.
    Habtemichael, Amelework D.
    Blumberg, Peter M.
    Lee, Jeewoo
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (19) : 8246 - 8252
  • [9] PROTEINASE-ACTIVATED RECEPTOR 2 SENSITIZES TRANSIENT RECEPTOR POTENTIAL VANILLOID 1, TRANSIENT RECEPTOR POTENTIAL VANILLOID 4, AND TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1 IN PACLITAXEL-INDUCED NEUROPATHIC PAIN
    Chen, Y.
    Yang, C.
    Wang, Z. J.
    NEUROSCIENCE, 2011, 193 : 440 - 451
  • [10] Transient Receptor Potential Vanilloid 1 and Xenobiotics
    Cuypers, E.
    Dabrowski, M.
    Horoszok, L.
    Terp, G. E.
    Tytgat, J.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2008, 7 (02) : 159 - 171